Opendata, web and dolomites

NovaTests

The first predictive test for radio-sensitivity. A step towards an improved and personalised radiation therapy cancer treatment.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovaTests project word cloud

Explore the words cloud of the NovaTests project. It provides you a very rough idea of what is the project "NovaTests" about.

efficient    ongoing    98    cancer    biology    sensitivity    robustness    first    lung    fast    2016    medical    rest    clinical    quality    patients    accuracy    cancers    healthy    patient    automating    cells    link    prostate    treatment    scientific    sme    prove    reliability    lives    unmet    fits    90    extension    deployment    active    time    validate    radiation    run    tolerance    analysing    directive    tests    move    direct    marking    therapy    sound    significantly    invested    intend    vitro    validation    each    indiscriminately    reg    week    stamped    evidences    efficiency    79    vary    treatments    meets    centre    serious    organs    2m    financial    survivors    february    stage    5m    tissues    instrument    radiotherapy    damaging    trial    novatests    pertaining    tumour    close    blood    novagray    million    ce    breast    radiosensitivity    tailor    market    diagnostic    plan    measuring    undergo    sensitive    predictive    regulatory    radio   

Project "NovaTests" data sheet

The following table provides information about the project.

Coordinator
NOVAGRAY 

Organization address
address: ROND POINT BENJAMIN FRANKLIN CAP OM CS 39521
city: MONTPELLIER
postcode: 34960
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.nova-gray.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVAGRAY FR (MONTPELLIER) coordinator 50˙000.00

Map

 Project objective

Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVATESTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVATESTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More